Paradigm Biopharma - Adapted therapies to meet unmet demand
Paradigm Biopharmaceuticals is a late-stage Australian drug developer focused on developing injectable pentosan polysulfate sodium (PPS). The...
792 Views
Paradigm Biopharmaceuticals (PAR AU): Comfortable Funding Position Through 2024
Paradigm is raising $66M via a fully underwritten placement that will entail a proforma cash position of $108.5M to fund it into 2024. The company...
495 Views
Paradigm Biopharmaceuticals (PAR AU): Concerns Persist Amid Deteriorating Financials
Paradigm’s widened net loss and depreciated cash balance raise our concern on its capability of conducting clinical activities and regulatory...
369 Views
Index Rebalance & ETF Flow Recap: HSI, HSCEI, HSTECH, HSCI, S&P/ASX, SET50, LIC, SBI Sumishin, Crown
This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...
711 Views
Paradigm Biopharmaceuticals (PAR AU): Concerns on First Potentially Commercialized Product
The company's dependence on a single molecule makes it a risky bet. Moreover, the inherent safety concern of the lead candidate may limit its...
476 Views